Stoll Receives Agilent Thought Leader Award
Agilent Technologies has awarded Dwight Stoll an Agilent Thought Leader Award in support of his research applying two‑dimensional liquid chromatography (2D‑LC) to biopharmaceutical analysis.
Agilent Technologies has awarded Dwight Stoll an Agilent Thought Leader Award in support of his research applying twoâdimensional liquid chromatography (2DâLC) to biopharmaceutical analysis.
“I am honoured to receive this award and very excited about Agilent’s support of the vision of my laboratory and our collaborators,” said Stoll, associate professor of analytical chemistry, Gustavus Adolphus College, Minnesota, USA, and future LCGC “LC Troubleshooting” columnist.
Stoll will lead a project on the use of 2D-LC in biopharmaceutical analysis that includes several international experts, including Michael Lämmerhofer, Douglas Richardson, and Davy Guillarme.
“We are pleased to support Dr. Stoll’s research,” said Stefan Schuette, vice president and general manager, Liquid Phase Separations Division, Agilent Technologies. “The collaborative nature of the research of Dr. Stoll and his international colleagues, combining both academia and industry, will undoubtedly accelerate the progress of these types of solutions for the biopharma industry.”
The Agilent Technologies Thought Leader Award promotes fundamental scientific advances by contributing financial support, products, and expertise to the research of influential thought leaders in the life sciences, diagnostics, and applied chemical markets.
If you would like to read more from Dwight Stoll he published his first “LC Troubleshooting” column in our February 2017 issue (1). Stoll will take over the column permanently in October 2017 from the retiring John Dolan.
Reference
- D.R. Stoll, LCGC Europe30(2), 80–83 (2017).
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
